Biologic Effects of Dehydroepiandrosterone (DHEA) in Humans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00099697|
Recruitment Status : Completed
First Posted : December 20, 2004
Last Update Posted : December 11, 2009
|Condition or disease||Intervention/treatment||Phase|
|Aging Obesity Insulin Resistance||Drug: DHEA||Not Applicable|
Studies on rats and mice have shown that the adrenal hormone dehydroepiandrosterone (DHEA) reduces abdominal visceral fat and protects against insulin resistance. This study was done to learn if DHEA replacement therapy decreases abdominal obesity and improves insulin action in humans.
Participants were randomly assigned to receive 50 mg per day of DHEA or a placebo at bedtime for 6 months. Participants underwent magnetic resonance imaging (MRI) and oral glucose tolerance tests at the beginning and conclusion of the study. Other tests included measurements of hormones and lipids.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||56 participants|
|Official Title:||Biologic Effects of DHEA in Humans|
|Study Start Date :||June 2001|
|Actual Primary Completion Date :||February 2004|
|Actual Study Completion Date :||February 2004|
- 6-month change in visceral and subcutaneous abdominal fat
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00099697
|United States, Missouri|
|Washington University School of Medicine|
|St. Louis, Missouri, United States, 63110|
|Principal Investigator:||John O. Holloszy, MD||Washington University School of Medicine|
|Principal Investigator:||Dennis T. Villareal, MD||Washington University School of Medicine|